title: ¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.
abstract: OBJECTIVE
  Maximum standardized uptake value on (18) F-fluorodeoxyglucose positron emission tomography was evaluated as a predictive surrogate marker in developing treatment strategies for recurrent or metastatic endometrial stromal sarcoma.
  
  
  METHODS
  Clinical information was obtained from records of patients with recurrent or metastatic endometrial stromal sarcoma who underwent surgery or biopsy following (18)F-fluorodeoxyglucose positron emission tomography. Pathological features - including estrogen receptor, progesterone receptor and Ki-67 expression - were immunohistochemically evaluated. We classified lesions as 'positron emission tomography positive' if the maximum standardized uptake value was 3.0 or higher. Clinicopathological features were compared between patients with positive and negative positron emission tomography findings by using the χ(2)-test.
  
  
  RESULTS
  Among eight recurrent and one metastatic endometrial stromal sarcoma patients, four (44%) had positron emission tomography-positive findings. Two positron emission tomography-positive patients were estrogen receptor negative and the five positron emission tomography-negative patients were estrogen receptor positive (P = 0.073). The Ki-67 index was 10% or higher in the four positron emission tomography-positive patients, but less than 5% in the five positron emission tomography-negative patients (P = 0.003). Three patients with positron emission tomography-positive tumors received more aggressive treatment (e.g. cytotoxic chemotherapy and additional surgery) than did those with positron emission tomography-negative tumors. One patient who died of disease had positron emission tomography-positive tumors, was negative for estrogen and progesterone receptors, and had a 20% Ki-67 index.
  
  
  CONCLUSIONS
  (18)F-Fluorodeoxyglucose uptake was associated with tumor biology of recurrent or metastatic endometrial stromal sarcoma. (18)F-fluorodeoxyglucose-positron emission tomography was useful for developing treatment strategies for recurrent or metastatic endometrial stromal sarcoma.
authors.affiliation: Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Department of Obstetrics and Gynecology, Meiwa General Hospital, Nishinomiya, Hyogo, Japan.
authors.forename: Kayo
authors.initials: K
authors.lastname: Inoue
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsubamoto
authors.forename: Shuji
authors.initials: S
authors.lastname: Kawata
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hao
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Naohiko
authors.initials: N
authors.lastname: Oku
authors.forename: Seiichi
authors.initials: S
authors.lastname: Hirota
mesh_terms: D000328:Adult; D016889:Endometrial Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D018203:Sarcoma, Endometrial Stromal / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000556:secondary*
chemical_list: D019394:Ki-67 Antigen; D019275:Radiopharmaceuticals; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D019788:Fluorodeoxyglucose F18
keywords: endometrial stromal sarcoma; immunohistochemistry; positron emission tomography; recurrence; standardized uptake value